Biocitech appoints new ceo

Jean-Francois Boussard becomes chief executive of French life science technology park on 1 April.

Jean-Francois Boussard will become chief executive of Biocitech, the French life science technology park in Paris, on 1 April. He replaces Jacques Lhomel, who is retiring to pursue personal projects.

Boussard joins Biocitech after a biotechnology career in academia and industry. From 1994, after six years as patents, licensing and legal director in a financial holding company, he became an independent consultant in enterprise creation and technology transfer. In 1998, he founded and was ceo of Substrat, a consultancy specialising in enterprise creation and management, project management and technology transfer in the field of biotechnology.

Prior to Substrat, Boussard was a manager for pharmaceuticals and biotechnology at France's innovation agency, Anvar, from 1982-88. From 1979-82, he was a biologist at LERS Synthelabo after an earlier spell as a research scientist at the University of Metz.

"I am looking forward to putting my scientific, legal and financial know-how to use to continue the rapid development of the park," said Boussard.

Biocitech provides offices, laboratories and technical and scientific services.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical

A bullish time for biotech

Biotechnology has changed healthcare radically over the past decade and its impact on the pharmaceutical sector is growing. Susan Birks reports on the impact of the biotech boom
Manufacturing

Watson-Marlow to showcase advanced fluid path solutions at COMPAMED 2025

The fluid transfer solution specialist will highlight a variety of peristaltic pumps and associated fluid path technologies at this years COMPAMED 2025, taking place from 17-20 Nov in Düsseldorf, Germany
Research & Development

Samsung Epis launches subsidiary Epis NexLab for next-gen biotech platform development

Epis NexLab will focus on transforming highly scalable peptide-related technologies into development platforms for the discovery of new drug candidates, including license-out or joint development with global pharmaceutical companies
You need to be a subscriber to read this article.
Click here to find out more.
Personal Protection

Gas safety in smaller pharmaceutical facilities

Whether in the production process, for essential sterilisation or decontamination, the use of gases is fundamental in the pharmaceutical and biopharmaceutical industries. Each gas is, however, accompanied by risks and can pose significant hazards to the health of employees
Analysis

Efficient extraction of proteins from bacterial cells

SoluLyse from Amsbio is a bacterial protein extraction reagent that provides a highly efficient yet gentle method for extracting soluble proteins from bacterial cells
Manufacturing

Piramal Pharma reports Q2 and H1 FY26 results amid CDMO challenges

CDMO growth impacted by inventory destocking while consumer healthcare posts mid-teen growth
Manufacturing

Abzena and Mabqi announce strategic partnership to offer integrated discovery through development solution

This collaboration will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution
Subscribe now